Enzychem Lifesciences Corporation

KOSDAQ 183490.KQ

Enzychem Lifesciences Corporation Price to Book Ratio (P/B) on January 14, 2025: 0.54

Enzychem Lifesciences Corporation Price to Book Ratio (P/B) is 0.54 on January 14, 2025, a -25.50% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Enzychem Lifesciences Corporation 52-week high Price to Book Ratio (P/B) is 0.89 on May 09, 2024, which is 63.87% above the current Price to Book Ratio (P/B).
Enzychem Lifesciences Corporation 52-week low Price to Book Ratio (P/B) is 0.39 on December 09, 2024, which is -27.72% below the current Price to Book Ratio (P/B).
Enzychem Lifesciences Corporation average Price to Book Ratio (P/B) for the last 52 weeks is 0.66.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

KOSDAQ: 183490.KQ

Enzychem Lifesciences Corporation

CEO	Ki-Young Sohn
IPO Date	April 5, 2017
Location	South Korea
Headquarters	aT Center
Employees	122
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Enzychem Lifesciences Corporation, a pharmaceutical company, focuses on the development of oral small molecule therapies for patients with unmet medical needs for oncology, metabolic diseases, and inflammatory diseases in South Korea. It is also developing potential therapies based on EC-18 technology platform to treat chemotherapy-induced neutropenia, chemoradiation therapy-induced oral mucositis, and acute radiation syndrome. The company was founded in 1999 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years